Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

CLN-049’s selected Phase 2 target doses showed anti-leukemic activity, with updated dose-escalation results still to be presented.

Rhea-AI Summary

Cullinan Therapeutics (Nasdaq: CGEM) will present CLN-049 and velinotamig research at the ASH Annual Meeting on December 12–15, 2026. Four posters will cover clinical and preclinical work.

The CLN-049 Phase 1 abstract reports anti-leukemic activity at selected Phase 2 target doses of 6 µg/kg and 12 µg/kg in relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. Cullinan describes a favorable safety profile with double step-up dosing; updated dose-escalation results will be presented. Other posters cover an ongoing CLN-049 combination trial in newly diagnosed leukemia, a velinotamig trial in two autoimmune blood disorders, and preclinical findings on targeting cells involved in those disorders.

Positive

• Minor pointCLN-049 Phase 1 findings show anti-leukemic activity at selected Phase 2 target doses of 6 µg/kg and 12 µg/kg.
• Minor pointCLN-049’s double step-up dosing regimen has a favorable safety profile, Cullinan reports.
• Minor pointVelinotamig preclinical data show selective targeting of BCMA-expressing B-lineage cells involved in autoimmune cytopenias.

Negative

• None.

Argus 15 min delay 84 alerts

-20.73% vs previous close $12.49 last price 3.1x rel. volume Open Argus

Details

Market move: CGEM -20.73% vs previous close. ASH clinical presentations

$12.48 – $17.00 Day Range

$803.47M Mkt Cap at Last Price

On Nov 4, the day this news came out, the latest delayed price for CGEM is 20.73% below the previous close. Our momentum scanner has recorded 84 alerts for this stock so far that day. The latest delayed price is $12.48. Relative volume is very high at 3.1x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Poster presentations: 4 presentations Selected Phase 2 target doses: 6 µg/kg and 12 µg/kg

Poster presentations

4 presentations

ASH Annual Meeting

Selected Phase 2 target doses

6 µg/kg and 12 µg/kg

CLN-049 Phase 1 dose-escalation abstract

Historical Context

2 past events · Latest: Oct 27

2 events

1. Oct 27

   Velinotamig trial clearance

   24h Move

   +2.1%

   U.S. and Australian clearance enabled initiation of a global Phase 1b/2a velinotamig trial.

2. Oct 08

   CLN-049 trial start

   24h Move

   -1.1%

   First patient dosed in CLN-049's planned registrational Phase 2 study for relapsed/refractory AML.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bispecific t cell engager, pharmacokinetics, pharmacodynamics, orphan drug designation, +1 more

5 terms

bispecific t cell engager medical

"a novel anti-FLT3 x anti-CD3 bispecific T cell engager"

A bispecific T cell engager is a lab-made protein that acts like a matchmaker between a cancer cell and a patient's immune killer cell (T cell), attaching to both so the T cell can recognize and destroy the cancer cell. For investors, these drugs matter because they can produce powerful, targeted effects that may lead to big clinical and commercial wins, but they also carry high development, safety and manufacturing risks that make outcomes binary and value volatile.

pharmacokinetics medical

"evaluating safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD)"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

pharmacodynamics medical

"evaluating safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD)"

Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.

orphan drug designation regulatory

"has received Orphan Drug designation and Fast Track designation"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

fast track designation regulatory

"has received Orphan Drug designation and Fast Track designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that two of its T cell engager programs, CLN-049, a FLT3xCD3 T cell engager, and velinotamig (CLN-803), a BCMAxCD3 T cell engager, will be featured across four poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15 in New Orleans, Louisiana.

Cullinan will present updated data from the CLN-049 Phase 1 dose escalation study in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The abstract reports the anti-leukemic activity of the selected Phase 2 target doses of 6 µg/kg and 12 µg/kg, and a favorable safety profile for the double step-up dosing regimen. Updated dose escalation results for the selected Phase 2 regimens will be further detailed in the poster presentation.

Additional posters include a Trial in Progress for CLN-049 in combination with azacitidine and venetoclax in newly diagnosed AML and a Trial in Progress for velinotamig in immune thrombocytopenia and warm autoimmune hemolytic anemia, which is also supported by a poster with new preclinical data demonstrating that velinotamig selectively targets BCMA-expressing B-lineage cells that drive autoimmune cytopenias.

Presentation Details 

CLN-049 Poster Presentations

Title: Updated anti-leukemia activity from a Phase 1 study of CLN-049, a novel anti-FLT3 x anti-CD3 bispecific T cell engager, in relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) 
Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II 
Session Date: December 13, 2026 
Session Time: 6:00 p.m. - 8:00 p.m. 
Session Location: MCCNO - Hall F 
Poster Number: 3385 

Title: Trials in Progress: A multicenter Phase 1b study of the bispecific T-cell engager CLN-049 in combination with venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) 
Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I 
Session Date: December 12, 2026 
Session Time: 5:30 p.m. - 7:30 p.m. 
Session Location: MCCNO - Hall F 
Poster Number: 1640 
 
Velinotamig (CLN-803) Poster Presentations  

Title: Velinotamig (CLN-803), a BCMA×CD3 Bispecific T-cell Engager, Targets B Cells and Plasma Cells That Drive Autoimmune Cytopenias 
Session Name: 703. Cellular Immunotherapies Other Than CAR-T Cells: Basic and Translational: Poster I 
Session Date: December 12, 2026 
Session Time: 5:30 p.m. - 7:30 p.m. 
Session Location: MCCNO - Hall F 
Poster Number: 2384 
 
Title: Trials in Progress: A Phase 1b/2a, Open-label Study of a Novel Subcutaneously Administered BCMAxCD3 T-Cell Engager Velinotamig in Relapsed/Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia 
Session Name: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II 
Session Date: December 13, 2026 
Session Time: 6:00 p.m. - 8:00 p.m. 
Session Location: MCCNO - Hall F 
Poster Number: 3001 
 
About CLN-049 

CLN-049 is a novel, investigational FLT3xCD3 T cell engager. CLN-049 is designed to target FLT3-expressing leukemia cells, offering a new immunotherapeutic approach for treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CLN-049 binds to both mutated and non-mutated FLT3, allowing targeted action regardless of FLT3 mutational status, making the investigational treatment widely applicable to a broad population. 

CLN-049 is being studied in a Phase 1/2, open-label, multicenter, multiple ascending dose study evaluating safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of intravenously (IV) administered CLN-049 in patients with relapsed/refractory AML or MDS (NCT05143996). 

CLN-049 is also being studied in a Phase 1/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and PD of IV-administered CLN-049 in combination with azacitidine and venetoclax in patients with newly diagnosed AML (NCT07722767). 

CLN-049 has received Orphan Drug designation and Fast Track designation from the U.S. FDA for the treatment of relapsed/refractory AML. 

About Acute Myeloid Leukemia (AML) 

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow, and the most common form of acute leukemia in adults.¹ It is characterized by the rapid growth of abnormal white blood cells that crowd out healthy cells, leading to infections, fatigue, and bleeding.² Each year in the U.S., approximately 23,000 people are diagnosed with AML, and about half as many lives are lost to the disease.³ Globally, AML affects an estimated 145,000 people annually, with approximately 130,000 deaths.⁴ 

Despite recent advances, outcomes for patients with AML remain poor, particularly for those with relapsed or refractory disease, where five-year survival is 10% or less.⁵ Patients with high-risk genetic features, such as complex karyotype or TP53 mutations, face especially limited options.^6,7 Intensive treatments like chemotherapy and stem cell transplantation may be inaccessible for many older patients due to severe side effects.⁷ Currently, there are no approved immunotherapies for AML, underscoring the urgent need for novel therapeutic approaches that can improve outcomes for patients and their families facing this life-threatening disease.⁸ 

About Velinotamig (CLN-803, GR1803)  

Velinotamig is a BCMAxCD3 T cell engager designed to redirect cytotoxic T cells to target BCMA-expressing cells including pathogenic, autoantibody-producing plasma cells. Velinotamig is engineered with high-affinity binding to BCMA and lower-affinity binding to CD3, with the goal of enhancing target cell depletion while minimizing non-specific T cell activation and associated cytokine-related toxicity. By targeting BCMA-expressing cells, velinotamig has the potential to address autoimmune diseases driven by pathogenic autoantibodies.  

Cullinan holds a global (ex-Greater China), all indication, exclusive license to velinotamig from Genrix Bio. Genrix Bio is evaluating velinotamig in a Phase 1b/2a clinical trial in patients with refractory systemic lupus erythematosus (SLE) in China. Cullinan Therapeutics is evaluating subcutaneously administered velinotamig in a global Phase 1b/2a study in patients with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia (NCT07738822).  

About Immune Thrombocytopenia (ITP)

Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease characterized by increased platelet destruction and impaired platelet production.⁹ Platelets play a critical role in blood clotting, and reduced platelet levels can lead to bruising, bleeding, debilitating fatigue, and impaired health-related quality of life.^9,10 In severe cases, bleeding may be life-threatening.⁹ ITP may present as an acute, self-limited condition or follow a chronic and relapsing course, particularly in adults.⁹ In the U.S., the prevalence of chronic primary ITP among adults has been estimated at 23.6 per 100,000 people, or approximately 62,000 adults.¹¹ Although currently available therapies can help manage platelet counts and reduce bleeding risk, many patients continue to experience relapses and the burden of ongoing disease management.^9,10 

About Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disease in which warm-reactive autoantibodies cause the premature destruction of red blood cells, resulting in anemia.¹² People living with wAIHA may experience debilitating fatigue, shortness of breath, jaundice, and other complications of anemia. The disease can be serious and potentially life-threatening.¹² The prevalence of wAIHA among adults in the U.S. is estimated at approximately 33,300 adults.^13,14 Achieving sustained disease control can remain challenging, particularly for patients with relapsing or refractory wAIHA, underscoring the need for additional treatment options.¹⁵  

About Cullinan Therapeutics 

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X. 

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: the clinical and therapeutic potential of CLN-049, our plans regarding future data presentations and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. 

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any INDs, NDAs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared or approved on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. 

Contacts: 

Investors 
Nick Smith 
+1 401.241.3516 
Nsmith@cullinantx.com 

Media 
Rose Weldon 
+1 215.801.7644 
Rweldon@cullinantx.com 

1. American Association for Cancer Research. (2025). Acute Myeloid Leukemia. https://www.aacr.org/patients-caregivers/cancer/acute-myeloid-leukemia/ 

2. National Cancer Institute. (2025). Acute Myeloid Leukemia Treatment (PDQ^®)–Patient Version. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq 

3. Leptidis J., et al. (2014). Fatal cardiac tamponade as the first manifestation of acute myeloid leukemia. Am J Emerg Med 32(10). https://doi.org/10.1016/j.ajem.2014.02.045 

4. National Cancer Institute. (2025). Cancer Stat Facts: Leukemia — Acute Myeloid Leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html 

5. Zhou, Y., et al. (2024). Global, regional, and national burden of acute myeloid leukemia, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Biomarker Research, 12(101). https://doi.org/10.1186/s40364-024-00649-y 

6. Moore, CG., et al. (2025). Treatment of Relapsed/Refractory AML—Novel Treatment Options Including Immunotherapy. Am J Hematol. (100)2. https://doi.org/10.1002/ajh.27584 

7. Shahzad, M., et al. (2024) What have we learned about TP53-mutated acute myeloid leukemia?. Blood Cancer J. 14(202). https://doi.org/10.1038/s41408-024-01186-5 

8. Kantarjian H., et al. (2021). Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11(2). https://doi.org/10.1038/s41408-021-00425-3 
9. Cooper, N. et al. (2019). Immune Thrombocytopenia. New England Journal of Medicine; 381:945-955. https://doi.org/10.1056/NEJMcp1810479
    
10. Cooper, N., et al. (2025). Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States. British Journal of Haematology, 207(3), 1038-1046. https://doi.org/10.1111/bjh.20257
     
11. Feudjo-Tepie, M. A., et al. (2008). Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. Journal of Thrombosis and Haemostasis; 6:711-712. https://doi.org/10.1111/j.1538-7836.2008.02911.x
     
12. Brodsky, R. A. (2019). Warm Autoimmune Hemolytic Anemia. New England Journal of Medicine, 381, 647-654. https://doi.org/10.1056/NEJMcp1900554
     
13. Krumme, A. et al. (2025). Prevalence and demographics of autoimmune hemolytic anemia in the United States. Blood, 146(Supplement 1):6239. https://doi.org/10.1182/blood-2025-6239 
     
14. Theodosia A. (2016) Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2016 (1): 690–697. https://doi.org/10.1182/asheducation-2016.1.690 
     
15. Barcellini, W., & Fattizzo, B. (2024). Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy. Transfusion Medicine and Hemotherapy, 51, 321-331. https://doi.org/10.1159/000540475

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What CLN-049 results will Cullinan present at ASH 2026?

Cullinan will present updated Phase 1 dose-escalation results for CLN-049 in relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. The abstract reports anti-leukemic activity at selected Phase 2 target doses of 6 µg/kg and 12 µg/kg. Cullinan describes a favorable safety profile for the double step-up dosing regimen.

Which treatments are being combined with Cullinan’s CLN-049 in newly diagnosed AML?

The trial combines CLN-049 with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia. The study evaluates safety, tolerability, how the body processes the treatment, and its effects on the body.